TAMPA, Fla.–(BUSINESS WIRE)– Oragenics, Inc. (NYSE American: OGEN) (the “Company”), a clinical stage
biotechnology company, today announced the publication of a research
paper titled “Blueprints for the rational design of therapeutic mutacin
1140 variants,” in Chemical Biology & Drug Design (CBDD).
The study, which can be accessed via https://onlinelibrary.wiley.com/doi/abs/10.1111/cbdd.13365
focused on structure-activity relationships of the lantibiotic Mutacin
1140 (MU1140) that expand the “drugability” of the MU1140 pipeline.
Lantibiotics are a novel class of peptide antibacterial compounds
naturally produced by a variety of Gram-positive bacterial strains to
attack competing bacteria. The outcomes from the study enabled
investigators, Kers et. al., to conceptualize variants of MU1140 that
eliminated the commonly found limitations in drug manufacturing that has
made the development of lantibiotics challenging, while also improving
efficacy, solubility, stability and longer half-life, as demonstrated in
biological systems. This is the first study that proposes that a
therapeutic variant of MU1140 would require multiple substitutions in
order to present all of the desired properties necessary to justify
Oragenics is developing OG716, a second generation multiple variant of
MU1140. The lead compound is derived from the company’s proprietary
lantibiotic discovery and characterization platform, and has shown
positive results in nonclinical testing, including the absence of
recurrence in animal models for C. difficile infection (CDI).
Dr. Alan Joslyn, Oragenics’ president and CEO stated: “The findings of
this study provide insight into a more streamlined and effective
development and manufacturing of this new class of anti-infectives.
OG716 is targeted for the treatment of C. difficile infections,
which have become an increasing health risk worldwide. New drug
resistant strains have caused an increase in mortality by more than 400
percent, which are expected to continue to increase until we are able to
counter against the resistance. We believe our compound may be an
effective treatment for recurrent CDI. In the meantime, we anticipate
submitting an Investigational New Drug application with the U.S. Food
and Drug Administration to begin clinical development during 2019.”
About Oragenics, Inc.
Oragenics, Inc. is focused on becoming a leader in novel antibiotics
against infectious disease and on developing effective treatments for
oral mucositis. The company has established two exclusive worldwide
channel collaborations with Intrexon Corporation and its subsidiaries,
which allow Oragenics to accelerate the development of much needed new
antibiotics that can work against resistant strains of bacteria and the
development of biotherapeutics for oral mucositis and other diseases and
conditions of the oral cavity, throat, and esophagus.
For more information about Oragenics, please visit www.oragenics.com.
Safe Harbor Statement: Under the Private Securities Litigation
Reform Act of 1995: This release includes forward-looking statements
that reflect management’s current views with respect to future events
and performance. These forward-looking statements are based on
management’s beliefs and assumptions and information currently
available. The words “ believe,” “ expect,” “ anticipate,” “ intend,” “
estimate,” “ project” and similar expressions that do not relate solely
to historical matters identify forward-looking statements. Investors
should be cautious in relying on forward-looking statements because they
are subject to a variety of risks, uncertainties, and other factors that
could cause actual results to differ materially from those expressed in
any such forward-looking statements. These factors include, but are not
limited to, risks and uncertainties described in our filings with the
U.S. Securities and Exchange Commission. Oragenics assumes no
responsibility to update any forward-looking statements contained in
this press release or with respect to the matters described herein.
Source: Oragenics, Inc.